Compare FLNT & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | CLNN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.9M | 85.7M |
| IPO Year | 2009 | N/A |
| Metric | FLNT | CLNN |
|---|---|---|
| Price | $2.93 | $6.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $33.75 |
| AVG Volume (30 Days) | ★ 218.9K | 93.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,764,000.00 | N/A |
| Revenue This Year | $5.89 | $17.64 |
| Revenue Next Year | $12.62 | $19,516.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $3.25 |
| 52 Week High | $4.15 | $13.50 |
| Indicator | FLNT | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 49.28 |
| Support Level | $2.95 | $5.46 |
| Resistance Level | $3.60 | $6.71 |
| Average True Range (ATR) | 0.31 | 0.39 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 69.72 | 58.39 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.